1242 GMT - GSK's plan to open a new research-and-development center in Cambridge, England, looks like a smart move that bodes well for its future prospects, Bernstein analysts say in a research note. "We view this as a sound investment as this site already houses a major [AstraZeneca] R&D hub and two world leading academic hospitals," the analysts say. "We think this should increase GSK's R&D productivity long term due to greater collaborations with academia." The U.K. drugmaker also plans more than 20 late-stage clinical trials to start this year, and is launching a three-year program to cut costs and fund investment in its late-stage portfolio, Bernstein says. Shares rise 1.4%.